Single dose of trastuzumab kick starts immune response in certain breast cancers

(Case Western Reserve University) A tumor's immune response to a single dose of the HER2 inhibitor trastuzumab predicted which patients with HER2-positive breast cancer would respond to the drug on a more long-term basis, according to the results of a study published recently in Clinical Cancer Research.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news